Decision tree for navigating nanotechnology-based products for medical application

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance to address the increasing interest and perceived lack of regulatory clarity regarding nanomedicines, specifically lipid nanoparticles and liposomes. This document introduces a decision tree designed to help researchers navigate the development process in accordance with existing frameworks from the International Council for Harmonisation (ICH) and various European regulatory agencies. The guidance identifies specific pathways for both new active substances and 'nanosimilar' products, helping developers understand how to apply technical requirements to nano-based drug delivery systems. While the decision tree provides a useful starting point, the MHRA clarifies that it does not cover medical devices and should not serve as a substitute for direct consultation. Therefore, the MHRA recommends that companies and researchers actively engage with the MHRA Innovation Office or schedule formal scientific advice meetings to discuss product-specific challenges and ensure full regulatory compliance during the development of these complex medicinal products.